FDA Approval For Lucentis

by Medindia Content Team on  July 6, 2006 at 12:13 PM Drug News   - G J E 4
FDA Approval For Lucentis
The first drug proven to significantly improve the vision of elderly patients was approved by the FDA on Friday.

The drug, Lucentis, is to treat age-related macular degeneration in its wet form, where blood vessels behind the retina leak, worsening vision and often leading to blindness. 90 percent of the 1.4 million Americans, who have lost their vision due to this degeneration, are estimated to have the wet form of the disease.

Lucentis is manufactured by Genentech, Inc., a Biotechnology Company based in South San Francisco, California. None of the other Food and Drug Administration (FDA)-approved treatments has been shown to significantly reverse vision deterioration, like Lucentis does. Lucentis cost $1,950 per injection, and should be used monthly or bimonthly.

Lucentis and Avastin, another Genentech cancer drug, block the same protein believed to instigate blood vessel growth. Dr. Hal Barron, Genentech chief medical officer said, "We believe Lucentis is a much better choice. I really believe when treating patients, you have to look at the wealth of data supporting its use and the quality of that data."

The FDA has not granted sanction for Avastin to be used in treating macular degeneration.

The National Eye Institute, part of the National Institutes of Health, has received an outside proposal to conduct a comparative study on Avastin and Lucentis in treating AMD.

The anticipated cost of Lucentis may limit its usage, while Avastin is far cheaper.

Neither drug is a complete cure for age-related macular degeneration.

The most commonly reported side- effects of Lucentis include conjunctival hemorrhage, eye pain, floaters, increased eye pressure and inflammation.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
My insurance company, Universal Sompo[IOB Healthcare] has rejected my claim for reimbusement of Lucentis injection on the plea that it is an OPD treatment in spite of the certification from the hospital (Sankara Nethralaya) that this is done in Operation Theatre as an inpatient. The treatment is a costly one and the rejection seems to be arbitrary. Could you please clarify under what clause the rejection is made? A.P.Viswanathan, Chennai
APV47 Friday, February 21, 2014

You May Also Like